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Abstract
Background: About 2/3 of the hemoglobin (Hb) variants 
do not show a charge difference to the wildtype entity 
but most of them differ in hydrophobicity. In addition to 
cation exchange chromatography, globin differentiation 
by liquid chromatography-tandem mass spectrometry 
(MS) was introduced. Hb Ullevaal was chosen as one 
example to demonstrate the performance of the approach.
Methods: Screening for Hb variants was performed using 
cation exchange HPLC. For globin separation reversed 
phase-LC/MS was performed. Tryptic digests of variants 
were separated on RP-HPLC with or without CID-fragmen-
tation and database search for identification of mutation 
bearing fragments. Sequencing of the β-globin gene has 
been performed.
Results: HbS, HbC, HbE, Hb South Florida and Hb Ulle-
vaal show typical and distinct patterns in the globin LC/
MS according to the theoretical protein data. The tryptic 
digest of Hb Ullevaal resulted in the identification of the 
respective mutated peptide βT9, which was confirmed by 
genetic sequencing.
Conclusions: By the application of globin-LC/MS two 
more dimensions for the Hb identification are added, 
hydropathicity and protein mass. With this workflow as 
screening procedure for Hb variants it is expected to be 
able to detect and identify the majority of variants with 
the exception of highly unstable variants, which cannot 
be determined in the peripheral blood at all. A negative 
result makes the presence of a significant Hb variant in 
the peripheral blood improbable.
Keywords: globin differentiation; Hb Ullevaal; hemo-
globin variants; mass spectrometry; tryptic digest.
Zusammenfassung
Hintergrund: Ungefähr 2/3 der Hämoglobin-Varianten 
weisen keine Ladungsdifferenz zum Wildtyp auf, aber die 
meisten davon unterscheiden sich in der Hydrophobizi-
tät. Ergänzend zur Kationenaustauscher-Chromatografie 
wurde die Globin-Differenzierung mittels LC-Tandem-MS 
eingeführt. Die Untersuchung von Hb Ullevaal wurde als 
Beispiel gewählt, da zu dieser Hb-Variante bisher noch 
keine Protein- oder Peptid-Daten publiziert wurden.
Methoden: Das Screening auf Hb-Varianten wird mittels 
Kationenaustauscher-HPLC durchgeführt. Die Globin-
Trennung erfolgte mittels RP-LC/MS. Nach dem Peptid-
verdau mit Trypsin wurden die Peptide mittels reversed 
phase-HPLC und anschließender Tandem-MS detektiert. 
Es erfolgte eine Datenbanksuche für die Identifizie-
rung mutierter Fragmente. Für die Bestätigung des Hb 
Ullevaal wurde die Sequenzierung des β-Globin-Genes 
durchgeführt.
Ergebnisse: Für HbS, HbC, HbE, Hb South Florida und Hb 
Ullevaal zeigten sich typische, den theoretischen Protein-
daten entsprechende Muster in der Globin-LC/MS. Mittels 
tryptischem Verdau konnte das mutierte Peptid von Hb 
*Correspondence: Dr. med. Matthias Weber, MVZ Labordiagnostik 
Karlsruhe, Am Rüppurer Schloss 1, 76199 Karlsruhe, Germany, 
E-Mail: matthias.weber@labor-karlsruhe.de
Julia J.M. Eekels: Erythrocyte Laboratory, University Children’s 
Hospital Zurich, Zurich, Switzerland
Bereitgestellt von | UZH Hauptbibliothek / Zentralbibliothek Zürich
Angemeldet
Heruntergeladen am | 19.02.18 19:18
138      Weber and Eekels: Screening and identification of Hb variants using LC tandem MS
Ullevaal identifiziert werden. Hb Ullevaal wurde durch 
Sequenzierung des β-Globin-Genes bestätigt.
Schlussfolgerungen: Durch die Einführung der Globin-LC/
MS stehen mit der Hydrophobizität und der Protein-Masse 
zwei weitere Dimensionen für die Hämoglobin-Identifi-
zierung zur Verfügung. Mittels dieses Vorgehens ist zu 
erwarten, dass ein Großteil der Hb-Varianten detektiert 
und identifiziert werden können. Eine Ausnahme bilden 
hyperinstabile Hb-Varianten, die im peripheren Blut nicht 
nachweisbar sind. Ein negatives Ergebnis macht das Vor-
liegen einer signifikanten Hb-Variante im peripheren Blut 
sehr unwahrscheinlich.
Schlüsselwörter: Globin-Differenzierung; Hämoglo-
bin-Varianten; Hb Ullevaal; Massenspektrometrie; 
Trypsin-Verdau.
Introduction
A total of 1268 genetically determined variants of hemo-
globin (Hb) have been reported to date [1]. Although 
about 26% of the variants already characterized have 
been shown to influence the physiologic behavior of 
the Hb, others do not seem to have an influence or are 
still not sufficiently characterized [1]. Often variants are 
discovered accidentally during determination of gly-
cated hemoglobin (HbA1c). Either the variant itself or a 
post-translational modified entity may interfere with 
the correct determination of HbA1c independent whether 
the determination is performed by chromatography or 
with antibody based assays [2–5]. Antibody based HbA1c 
assays are principally not able to detect variants. Even 
variants which are prevalent in several populations have 
a direct or indirect influence on the measured HbA1c 
what makes it desirable to gain knowledge about their 
 presence [6, 7].
Notwithstanding the genetic testing is considered 
to be the gold standard for the detection of Hb variants 
neither comparably higher costs nor the necessary efforts 
justify the use of it as a first line screening procedure. 
While about 2/3 of the variants do not show a charge 
difference to the wildtype entity, >95% of them differ in 
hydrophobicity (Figure 1) [8]. This implies that screening 
procedures relying only on differences of the isoelectric 
point probably will be insensitive to 2/3 of possible vari-
ants. Beside this it recently has been shown that phe-
notype data can be indispensable for a comprehensive 
identification of an Hb variant [9]. Hb Ullevaal was chosen 
as an example because the first description is based only 
on genetic data while no further experimental data at the 
protein level have been published [10].
Materials and methods
Patients
The patient sample described here for Hb variant determination 
has been drawn from a 78-year-old German male which showed an 
interfering peak in the HbA1c determination by ion exchange HPLC 
 (Figure 2). The informed consent of the patient was obtained.
For all procedures described here with K3-EDTA anticoagulated 
blood samples were used.
Several examples of the globin separation of abnormal Hbs are 
obtained from anticoagulated routine samples for which Hb diagnos-
tic was requested.
Materials
Tissue culture grade trypsin from porcine pancreas, calcium chloride, 
N-p-Tosyl-L-phenylalanine chloromethyl ketone (TPCK), dithiothrei-
tol (DTT), iodoacetamide and trifluoro acetic acid (TFA) were pur-
chased from Sigma-Aldrich, Munich, Germany. Tris(hydroxymethyl)
methylamine and sodium chloride were obtained from Merck, 
Darmstadt, Germany. LCMS-grade methanol and acetonitrile were 
purchased from J.T. Baker, Netherlands. LCMS-grade water was used 
for all applications and was obtained from a Milli-Q Reference water 
purification system, Merck Millipore, Darmstadt, Germany.
0%
20%
40%
60%
80%
100%
|∆pI| > 0 |∆m/z| > 6 |∆H| > 0
Single parameter |∆pI| = 0 & second parameter
Figure 1: Percentage of variants of α- and β-globin with a single 
parameter differing from wild type (blue) and percentage of variants 
with no charge difference (ΔpI), but differing mass (ΔM) or differing 
hydropathicity (ΔH) (orange).
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Methods
The blood count (Sysmex-2100 XE, Kobe, Japan) and a cation 
exchange separation of the intact Hb (Tosoh G8, Tokyo, Japan, 
thalassemia mode) have been performed according to the instruc-
tions of the manufacturer.
A stock solution of trypsin was prepared in aliquots of 1 mg/mL 
in 1  mmol/L hydrochloric acid stabilized with 20  mmol calcium 
chloride and stored at −80 °C. Stock solutions of 0.9% sodium chlo-
ride in water, 0.5  mol/L Tris-HCl (pH 8), 50  mmol/L DTT in water, 
100 mmol/L iodoacetamide in water and 10 mmol/L TPCK in metha-
nol have been prepared.
For sample preparation K3-EDTA-anticoagulated blood sam-
ples were centrifuged 5  min at 10,000 g at ambient temperature, 
the plasma was removed, the red blood cells one time washed with 
saline at 4 °C and for hemolysis the five-fold amount of water at 4 °C 
was added, the sample vortexed and centrifuged at 20,000 g/10 min. 
The supernatant was adjusted with water to a Hb content of about 
10 mg/mL.
The tryptic digest was performed with 25 μL of the hemolysed 
sample by adding 5 μL Tris-buffer and 3.5 μL DTT-solution at 37 °C 
for 30 min, 3.85 μL iodoacetamide solution at 37 °C for 30 min, 10 μL 
DTT at 37 °C for 30 min and 5 μL acetonitrile, 0.5 μL TPCK-solution 
and 5 μL trypsin solution for 20 h at 37 °C. The digest was stopped by 
adding 5 μL TFA.
The liquid chromatography mass spectrometry was performed 
on a Thermo Vantage system consisting of an Ultimate UHPLC 
and TSQ Vantage mass spectrometer (Thermo Fisher Scientific, 
Dreieich, Germany) used with positive ESI. The globin separa-
tion was performed on a RP-column (Aeris Widebore 2.1 × 250 mm, 
 Phenomenex, Torrance, USA) using water/TFA 0.1% (mobile 
phase A) and acetonitrile/TFA 0.1% (mobile phase B) as gradient 
(39% B–46% B in 15  min and 46% B–100% B in 1  min, flow rate 
0.5 mL/min).
The separation of the tryptic peptides was performed on a 
reversed phase-column (Aeris Peptide 2.1 × 250  mm, Phenomenex) 
using water/0.1% formic acid (mobile phase A) and methanol/0.1% 
formic acid (mobile phase B) as linear gradient (5% B–25% B in 
30 min and to 60% B–100% B in 10 min).
As parameters for the HESI ion source in the positive mode a 
spray voltage of 3000 volt, vaporizer temperature of 550 °C, sheath 
gas pressure setting 50, auxiliary gas setting 20 and a capillary tem-
perature of 250 °C have been used.
The scan parameters for the intact globin scan were set to full 
scan 750–1500 m/z with a mass resolution width setting of 0.2 m/z 
and a scan time of 0.75 s for routine globin analysis. Tryptic peptides 
are first analyzed by a survey scan with 220–1500 m/z using a mass 
resolution width setting of 0.5 m/z and a scan time of 0.5 s. As next 
step under the same chromatographic conditions data dependent 
scans are performed with 1 mTorr argon as collision gas to gain frag-
ment ion spectra of the respective tryptic peptides. Alternatively tar-
geted fragment ion spectra are produced from the formerly identified 
aberrant doubly charged peptides.
Proteomic data analysis
The globin mass was derived by spectra deconvolution of the multi-
ply charged globin ions (charge state 11+ to 20+) [11]. For mass cali-
bration of the algorithm, the α-globin spectrum with nominal m/z of 
15126.3 of the uncharged globin was used as m/z reference.
In the tryptic digest, the mutation bearing peptide was identified 
by comparing the survey scan of the patient sample with a wild type 
control sample. The chromatograms are checked for new appearing 
peaks and corresponding peaks with reduced intensity compared to 
the wild type sample. As first validation step, the mass difference of 
the putative mutated peptide and the corresponding wild type pep-
tide has to be in accordance with the formerly estimated mass differ-
ence of the intact globins.
For identification of tryptic peptides a FASTA file of wild type 
and single point mutated α- and β-globins and the tryptic peptides 
to be expected was prepared. Raw spectral fragmentation data of the 
respective peptide were merged. For identification of the tryptic pep-
tides The GPM X!Tandem [12] was used to fit the spectra against the 
Figure 2: Chromatogram of HbA1c determination of Hb Ullevaal with Tosoh G8, Variant mode.
The grey shaded peak represents HbA1c. The peak (*) probably represents glycated Hb Ullevaal or another derivative causing an interference 
hindering the integration algorithm to correctly determine the HbA1c.
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previously prepared FASTA library. The result then has to be graphi-
cally validated.
Genetic analysis
For single cases of HbS, HbE and Hb South Florida and Hb Ullevaal 
the mutations by genetic sequencing have been confirmed as well 
(data not shown). Exon 1 + 2 were amplified with primers DHPLC1 For-
ward (5′-GCA ATT TGT ACT GAT GGT ATG G-3′) and DHPLC3 Reverse 
(5′-CCA CAC TGA TGC AAT CAT TCG-3′) and exon 3  with primers 
DHPLC4 Forward (5′-CAT CAG TGT GGA AGT CTC AGG-3′) and HPLC7 
Reverse (5′-TTA AAT GCA CTG ACC TCC CAC-3′) using Accustart II PCR 
master mix according to manufacturer’s instructions.
Sequencing was done with the same primers at Microsynth. 
Sequences were analyzed by aligning them to HBB Refseq 
NG_000007.3.
Results
Hematological investigations of the patient sample 
bearing Hb Ullevaal showed a macrocytosis and hyper-
chromia of the red blood cells (Ery count 4.4 T/L, Hb 14.8 
g/dL, MCH 34 pg, HCT 44.3%, MCV 100 fl, RDW 12.9%, 
MCHC 33 g/dL). This is different from the already pub-
lished case in which the results have been within the 
reference range [10]. ALT and γ-glutamyl transferase are 
elevated, but lactate dehydrogenase, cobalamin and folic 
acid were found in the reference range. However, neither 
holotranscobalamine nor methylmalonic acid have 
been determined so that a pernicious anemia cannot be 
excluded as cause for the macrocytosis. The elevated 
liver enzymes point to the possible presence of other 
pathologies. The blood sample was submitted for deter-
mination of glycated Hb, which showed a fraction inter-
fering with the glycated Hb and prevented correct peak 
integration (Figure 2).
Ion exchange HPLC
The cation exchange separation of intact Hb on the Tosoh 
G8 represents a basic technique requiring a charge dif-
ference of the respective variant. Common wide spread 
variants (HbS, HbE, HbC) easily can be discovered and 
quantified by this method. The studied patient sample 
containing Hb Ullevaal does not show any abnormality in 
this ion exchange chromatography (Figure 3).
Globin-RP-LC/MS
For the patient sample a distinct extra peak in the globin 
separation was visible representing about 50% of the 
β-globin, thus pointing to a heterozygous β-globin variant. 
The deconvolution of the multiply charged globin spec-
trum yields a single mass peak of 15,854 m/z which cor-
responds to a difference of −14 m/z compared to the wild 
type β chain (Figure 4). Only 40 of 861 possible single point 
mutations of β-globin are expected to show this pattern [8].
Tryptic digest
In the peptide map in comparison with a wild type sample 
an additional peptide was detected, at the same time 
Figure 3: Cation exchange chromatogram of heterozygous Hb Ullevaal (Tosoh G8, thalassemia mode).
This represents a normal finding without any suspicious fraction.
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another peptide shows a markedly reduced intensity 
(Figure 5). The difference in the peptide mass proofed to 
be −14 m/z, hence it is identical with the mass difference of 
the undigested globins. The wild type peptide was meas-
ured to have a mass of 1668.5 m/z, corresponding to βT9. 
In this tryptic peptide 7 mutations are expected to show 
similar characteristics.
For the final identification a product ion scan of 
the doubly charged aberrant peptide was performed. 
Fifteen product ion spectra have been obtained, which 
are used for identification with the X!Tandem algorithm 
of The GPM. This unequivocally resulted in the identifi-
cation of Hb Ullevaal (Figure 6), other database hits are 
not found. Furthermore, if the prepared globin-muta-
tion-fragment database was not included in the search, 
not any hit was found within all available human and 
other databases.
Thus, the exchange β78(EF2)Leu→Val has been 
confirmed.
Genetic testing
Sequencing of the β-globin gene detected a heterozygote 
C→G transition of the first nucleotide of codon 78. This 
CTG→GTC transition leads to the Leu→Val exchange 
in the β-chain as described above. The variant was thus 
identified as Hb Ullevaal also by DNA sequencing.
Discussion
Until today, separation techniques relying on a charge 
difference are the main basis for screening if Hb variants 
are suspected. This includes chromatographic or electro-
phoretic procedures like capillary zone electrophoresis. 
Although this criterion is important and brings along the 
detection of the Hb variants most frequently found, the 
larger part of possible Hb variants are not expected to show 
m/z
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Figure 4: A: Deconvolution results of the β globin ESI+ mass spectrum.
(A) Wild type, (B) Hb Ullevaal (red). B: Spectrum of the multiply charged β-globin.
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a charge difference and probably will be neglected by this 
approach. Nevertheless, an extra peak in the ion exchange 
chromatography for determination of glycated Hb led to 
the suspicion in this case of Hb Ullevaal. However, there 
are secondary effects possibly caused by conformational 
changes as a consequence of the mutation. In other cases 
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post-translational modifications led to the appearance of 
an interfering fraction while the mutated Hb itself remains 
cryptic, superimposed by HbA0.
Several publications have shown the benefit of the 
additional use of mass spectrometric approaches in the 
field of Hb analysis [8, 9, 13–16].
The most straightforward approach seems to be 
MALDI-ToF-MS of the crude Hb mixture. This method has 
the advantage of being fast and without a lot of sample 
preparation yielding mass information. On the other hand 
it has been shown, that even a MS yielding high mass 
resolution of R = 200,000 does not allow the discrimi-
nation of mass differences of 1 or 2 m/z whereas a mass 
difference of 9 m/z is clearly distinguishable [8]. Conse-
quently enhancing mass resolution does not necessarily 
yield unambiguous globin identification. Furthermore, 
despite the growing use of orbitrap and ToF-MS not in 
every laboratory a high resolution MS device is available. 
Even though the globin separation and the mass spectro-
metry by MALDI-TOF-MS are already studied as separate 
techniques for the examination of Hb variants [17], still no 
data are available concerning the combination of globin 
separation and MS. Looking at single point mutations of 
the α- and β-globin only for about 40% of the variants 
charge differences are to be expected (Figure 1). Because 
of the only use of separation techniques relying on a dif-
fering isoelectric point the frequency of Hb variants neces-
sarily are by far underestimated.
In contrast more than 95% of the mutations do show 
a difference in hydropathicity [8]. Interestingly based on 
theoretical data all of the variants show at least one of 
the studied criteria to differ from wild type. Consequently, 
the use of globin separation in combination with full 
scan mass spectrometry and ion exchange HPLC allows 
a screening for Hb variants with a reduced probability to 
gain false negative results. The example of Hb Ullevaal 
showed that a comparably small structural difference of 
one methyl group (Leu→Val) in a 142 amino acid protein 
causes a rather different chromatographic behavior of the 
variant globin and can be detected. At the same time the 
identity of the variants commonly found can be verified 
more precisely even on protein level (Figure 7). In case the 
variant globin is separated chromatographically from the 
wild type entity this also allows a sufficiently precise esti-
mation of the m/z without any interference. According to 
our experience it is possible to detect a mass difference 
down to 1 m/z, as regularly seen in the case of HbE (data 
not shown).
Our data describe the usefulness of an approach which 
could be applied on a triple quadrupole MS. Other reports 
describe the preparative separation of the aberrant Hb or 
globin chain prior to the MS analysis or fragmentation 
experiments. Although this approach is a very thorough 
basis for further analysis of the variant Hb, for a routine 
procedure it is too cumbersome [13].
The usefulness of the globin separation is mainly 
based on differences in hydropathicity though adds a 
different separation principle. According to our data this 
parameter contributes a further independent criterion in 
identification of an Hb variant (Figure 7). However, our 
experience does not show a good correlation of the theo-
retically calculated hydropathicity [18] with the retention 
coefficient of the respective globin. This probably can be 
explained by secondary effects caused by conformational 
changes, ion pair effects of TFA, secondary interactions 
with the column material and others. As a consequence 
precise estimation of the hydropathicity from the reten-
tion behavior is not possible. Furthermore, it cannot com-
pletely be excluded, that post-translational modifications 
or instabilities of respective functional residues cause a 
Hb S
Hb C
Hb E
Hb South Florida
Hb Ullevaal
β α
∆m/z = –30
∆m/z = –1
∆m/z = –1
∆m/z = +163
∆m/z = +205
∗
∆m/z = –14
Figure 7: Globin separation of different heterozygous Hb variants.
The aberrant globin entity is marked by the red filling and annotated 
with the m/z difference. (*) indicates the acetylated fraction of Hb 
South Florida.
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different chemical structure of the phenotype compared 
to the situation expected from the genetics [19].
Finally with the combination of the mass and reten-
tion information of the globin and the tryptic peptides, it 
is possible to gain fragment spectra containing enough 
information for the identification of most of the question-
able peptides. Furthermore, knowing the affected globin 
entity provides a basis for possible subsequent targeted 
genetic analysis.
Basilico et al. describe the use of the peptide map or 
identification of the mutation bearing peptide by means 
of the respective m/z and Δm/z with subsequent align-
ment to a variant peptide database using the SEQUEST 
algorithm as primary strategy [14]. However, this implies 
to perform a tryptic digest of every sample to be examined 
and therefore would not be considered as appropriate 
method for a routine screening of Hb variants.
Although the detection of mutated tryptic peptides 
by MRM using proteotypic mass transitions is a selective 
and sensitive approach, it is not possible to use it for the 
screening of more than 2103 possible single point muta-
tions by technical reason [8].
The approach of screening Hb variants on the protein 
level can sometimes fail to detect a variant. If the muta-
tion leads to an unstable tryptic peptide, the only hint 
for the variant present may be a reduced amount of the 
concerned wildtype peptide. In some cases an amino acid 
newly introduced by a mutation causes post-translational 
modifications though more complex and ambiguous 
results are the consequence. For instance, in the case of 
Hb South Florida two different new globin entities are 
found in the globin LC/MS and in the peptide map as 
well. This is a consequence of a phenomenon that about 
20% of the proteins having a methionine as N-terminus 
are acetylated [20]. In principle higher degrees of oxida-
tion, deamidation and glycosylation as a consequence of 
a mutation could be considered as well and can result in 
misleading patterns in the globin separation and subse-
quent interpretation of the mass difference as well. On 
the other hand variants with a genetic basis exceeding a 
single point mutation are likely to be found and character-
ized by this concept as well.
Variants that are very unstable probably cannot be 
found in the peripheral red blood cells at all thus can 
only be discovered by genetic sequencing of the respec-
tive globin gene. Furthermore, globins of lower abun-
dance like γ- and δ- globin are hardly to be detected by 
our routine screening due to the signal-to-noise ratio. The 
characterization in principle is possible as well if such a 
low abundance variant is suspected. In so far characteri-
zation of both protein and DNA level may be important 
at least in some cases. Hyperinstable variants can only 
be detected by genetic sequencing because of lack of the 
gene product in the peripheral blood.
In the future the possible benefit of a high resolution 
MS should be evaluated especially concerning the use 
of de novo sequencing techniques. Another issue to be 
addressed is the possibility to automate the whole work-
flow, which is done manually to date. One other question 
to be answered is, in how far comorbidities with Hb vari-
ants called “clinically still” play a role and other diagnos-
tic measures beside HbA1c are influenced [19]. This could 
be the case, if “clinically still” variants appear in combina-
tion with sickle cell anemia were they can have effects in 
either direction.
Unless the use of mass spectrometry requires trained 
staff and generates some costs as well, according to our 
experience the stepwise approach described here is 
appropriate for routine use, reduces the ambiguity oft the 
results, helps detecting and identifying the questionable 
variant and reduces the danger of missing a Hb variant 
during a screening process.
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